Výsledky vyhledávání - "Jorn Kaspers"

Akademický článek

Transfer of Cellular Content from the Allogeneic Cell-Based Cancer Vaccine DCP-001 to Host Dendritic Cells Hinges on Phosphatidylserine and Is Enhanced by CD47 Blockade

Autor: Haoxiao Zuo, Marie-José C. van Lierop, Jorn Kaspers, Remco Bos, Anneke Reurs, Saheli Sarkar, Tania Konry, Alwin Kamermans, Gijs Kooij, Helga E. de Vries, Tanja D. de Gruijl, Alex Karlsson-Parra, Erik H. Manting, Ada M. Kruisbeek, Satwinder Kaur Singh

Publikováno v: Cells, Vol 10, Iss 11, p 3233 (2021)

DCP-001 is a cell-based cancer vaccine generated by differentiation and maturation of cells from the human DCOne myeloid leukemic cell line. This results in a vaccine comprising a broad array of endogenous tumor antigens combined with a mature dendri

Externí odkaz: https://doaj.org/article/467c11dcb8d4413a8aaeb2c376d6e894

Zobrazit plný text záznamu

Plný text ve formátu HTML

A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia

Autor: Ada M. Kruisbeek, Tanja D. de Gruijl, Malika Koppes, Jorn Kaspers, Sandra van Wetering, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Saskia J. A. M. Santegoets, Yvonne den Hartog, Corien Eeltink, Satwinder Kaur Singh

Publikováno v: Cancer Immunology, Immunotherapy
Cancer Immunology and Immunotherapy, 67(10), 1505-1518. Springer Science and Business Media Deutschland GmbH
van de Loosdrecht, A A, van Wetering, S, Santegoets, S J A M, Singh, S K, Eeltink, C M, den Hartog, Y, Koppes, M, Kaspers, J, Ossenkoppele, G J, Kruisbeek, A M & de Gruijl, T D 2018, ' A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia ', Cancer Immunology and Immunotherapy, vol. 67, no. 10, pp. 1505-1518 . https://doi.org/10.1007/s00262-018-2198-9
Cancer Immunology, Immunotherapy, 67(10), 1505-1518

In elderly acute myeloid leukemia (AML) patients post-remission treatment options are associated with high comorbidity rates and poor survival. Dendritic cell (DC)-based immunotherapy is a promising alternative treatment strategy. A novel allogeneic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef36f686f0fe8c6ea1435348e856c7c3
https://doi.org/10.1007/s00262-018-2198-9

Zobrazit plný text záznamu

Transfer of Cellular Content from the Allogeneic Cell-Based Cancer Vaccine DCP-001 to Host Dendritic Cells Hinges on Phosphatidylserine and Is Enhanced by CD47 Blockade

Autor: Remco Bos, Ada M. Kruisbeek, Anneke W. Reurs, Saheli Sarkar, G. Kooij, Jorn Kaspers, Erik Manting, Helga E. de Vries, Haoxiao Zuo, Alwin Kamermans, Alex Karlsson-Parra, Marie-José van Lierop, Satwinder Kaur Singh, Tania Konry, Tanja D. de Gruijl

Publikováno v: Cells, 10(11):3233. MDPI Multidisciplinary Digital Publishing Institute
Cells, Vol 10, Iss 3233, p 3233 (2021)
Cells
Cells, 10(11). MDPI Multidisciplinary Digital Publishing Institute
Zuo, H, van Lierop, M-J C, Kaspers, J, Bos, R, Reurs, A, Sarkar, S, Konry, T, Kamermans, A, Kooij, G, de Vries, H E, de Gruijl, T D, Karlsson-Parra, A, Manting, E H, Kruisbeek, A M & Singh, S K 2021, ' Transfer of Cellular Content from the Allogeneic Cell-Based Cancer Vaccine DCP-001 to Host Dendritic Cells Hinges on Phosphatidylserine and Is Enhanced by CD47 Blockade ', Cells, vol. 10, no. 11, 3233 . https://doi.org/10.3390/cells10113233
Volume 10
Issue 11

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19cff7c9de1aae846c1da1ceefff581a
https://doi.org/10.3390/cells10113233

Zobrazit plný text záznamu

Plný text ve formátu HTML

219 CD47 and phosphatidylserine contribute to the interaction between antigen presenting cells and the allogeneic cell-based relapse vaccine DCP-001

Autor: Haoxiao Zuo, Satwinder Kaur Singh, Marie-José Van Lierop, Jorn Kaspers, Remco Bos, Alwin Kamermans, Helga E de Vries, Tanja de Gruijl, Ada Kruisbeek, Erik Manting

Publikováno v: Journal for ImmunoTherapy of Cancer. 9:A232-A232

BackgroundDCP-001 is a cancer relapse vaccine derived from the DCOne® human leukemic cell line. During manufacturing, DCOne® cells are shifted towards a mature dendritic cell (mDC) phenotype, combining an endogenous tumor antigen repertoire (e.g. W

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::667bb07a1c9ba56bde96fc00f4f2716d
https://doi.org/10.1136/jitc-2021-sitc2021.219

Zobrazit plný text záznamu

Serum-free transient protein production system based on adenoviral vector and PER.C6 technology: high yield and preserved bioactivity

Autor: R. van der Vlugt, Lennart Holterman, Jaap Goudsmit, Menzo J. E. Havenga, Martin H. Koldijk, Jorn Kaspers, Guus Hateboer, E. Heemskerk, Ronald Vogels, Shirley Smits, I. Melis, K. Brouwer, Govert Johan Schouten

Publikováno v: Biotechnology and Bioengineering
Biotechnology and bioengineering, 100(2), 273-283. Wiley-VCH Verlag

Stable E1 transformed cells, like PER.C6, are able to grow at scale and to high cell densities. E1‐deleted adenoviruses replicate to high titer in PER.C6 cells whereas subsequent deletion of E2A from the vector results in absence of replication in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da3a32e83ef4ce79caf18ab0d9255a46
https://doi.org/10.1002/bit.21757

Zobrazit plný text záznamu

Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells

Publikováno v: Journal of general virology, 87(Part 8), 2135-2143. Society for General Microbiology

Adenoviral vectors based on adenovirus type 35 (rAd35) have the advantage of low natural vector immunity and induce strong, insert-specific T- and B-cell responses, making them prime-candidate vaccine carriers. However, severe vector-genome instabili

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14ab29129c85d052e2d58b210d898735
https://doi.org/10.1099/vir.0.81956-0

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání